Loading
Loading
Research Overview
Potent NNMT (nicotinamide N-methyltransferase) inhibitor; NNMT normally consumes methyl donors that would otherwise support NAD+ synthesis, so its inhibition raises intracellular NAD+ and SAM levels, increasing mitochondrial activity and reducing lipid accumulation in preclinical models.
Overview
5-Amino-1MQ is a cell-permeable NNMT inhibitor studied in preclinical settings for its ability to reduce NNMT enzymatic activity and alter NAD+ metabolism. By inhibiting NNMT, the compound reduces nicotinamide catabolism, potentially elevating intracellular NAD+ pools and influencing sirtuin activity, epigenetic methyl donor availability, and adipocyte biology.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, 5-amino-1mq (nnmt inhibitor) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Potent NNMT (nicotinamide N-methyltransferase) inhibitor; NNMT normally consumes methyl donors that would otherwise support NAD+ synthesis, so its inhibition raises intracellular NAD+ and SAM levels, increasing mitochondrial activity and reducing lipid accumulation in preclinical models.
Field Signal
Community & Anecdotal Signal
Community signal is thin and quality-variable. 5-Amino-1MQ occupies a similar early-adopter position to SLU-PP-332, with limited personal experience reports and discussion that often conflates different compounds in the NNMT inhibitor class. Fat loss and metabolic support are the primary framing in community discussion, driven by the mechanism rather than accumulated outcome data. r/Peptides threads exist but are short. Sourcing reliability concerns are prominent given the compound's niche status and limited commercial history. The community interested in 5-Amino-1MQ tends to be highly researc
Anecdotal reports are not clinical evidence. Signal may reflect sourcing quality, dosing variation, and expectation bias.
Support
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
